Log in

NASDAQ:PTLAPortola Pharmaceuticals Stock Price, Forecast & News

$18.03
0.00 (0.00 %)
(As of 07/16/2020)
Add
Compare
Today's Range
$18.03
Now: $18.03
$18.03
50-Day Range
$17.97
MA: $18.02
$18.03
52-Week Range
$5.31
Now: $18.03
$31.73
VolumeN/A
Average Volume3.17 million shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
Read More
Portola Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$116.64 million
Book Value$1.67 per share

Profitability

Net Income$-290,660,000.00
Net Margins-232.73%

Miscellaneous

Employees324
Market Cap$1.42 billion
Next Earnings DateN/A
OptionableOptionable
$18.03
0.00 (0.00 %)
(As of 07/16/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

How has Portola Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Portola Pharmaceuticals' stock was trading at $8.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PTLA stock has increased by 111.1% and is now trading at $18.03.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Portola Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Portola Pharmaceuticals
.

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analyst estimates of $33.88 million. Portola Pharmaceuticals had a negative return on equity of 267.86% and a negative net margin of 232.73%. Portola Pharmaceuticals's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the company posted ($1.02) earnings per share.
View Portola Pharmaceuticals' earnings history
.

What price target have analysts set for PTLA?

7 analysts have issued 12-month price objectives for Portola Pharmaceuticals' shares. Their forecasts range from $17.00 to $44.00. On average, they expect Portola Pharmaceuticals' share price to reach $28.17 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price.
View analysts' price targets for Portola Pharmaceuticals
.

Has Portola Pharmaceuticals been receiving favorable news coverage?

News stories about PTLA stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Portola Pharmaceuticals
.

Are investors shorting Portola Pharmaceuticals?

Portola Pharmaceuticals saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 13,680,000 shares, an increase of 22.9% from the May 14th total of 11,130,000 shares. Based on an average daily trading volume, of 4,260,000 shares, the days-to-cover ratio is presently 3.2 days.
View Portola Pharmaceuticals' Short Interest
.

Who are some of Portola Pharmaceuticals' key competitors?

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Exelixis (EXEL), Amarin (AMRN), NVIDIA (NVDA), Geron (GERN), Inovio Pharmaceuticals (INO) and ACADIA Pharmaceuticals (ACAD).

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the following people:
  • Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
  • Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
  • Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
  • Cara Miller, VP of Investor Relations and Corp. Communications
  • Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.93%), Goldman Sachs Group Inc. (4.57%), Water Island Capital LLC (2.99%), ARP Americas LP (2.81%), Healthcare of Ontario Pension Plan Trust Fund (1.80%) and Barclays PLC (1.66%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Hollings Renton, Jeffrey W Bird and Mardi Dier.
View institutional ownership trends for Portola Pharmaceuticals
.

Which major investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management Fund Advisors L.P., New York State Common Retirement Fund, Macquarie Group Ltd., State of Wisconsin Investment Board, Bank of America Corp DE, Russell Investments Group Ltd., Bank of New York Mellon Corp, and SG Americas Securities LLC.
View insider buying and selling activity for Portola Pharmaceuticals
.

Which major investors are buying Portola Pharmaceuticals stock?

PTLA stock was bought by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Goldman Sachs Group Inc., ARP Americas LP, Healthcare of Ontario Pension Plan Trust Fund, Barclays PLC, Bardin Hill Management Partners LP, Gabelli Funds LLC, and Glazer Capital LLC.
View insider buying and selling activity for Portola Pharmaceuticals
.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $18.03.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.42 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290,660,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. Portola Pharmaceuticals employs 324 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.